24/7 Wall Street
09 Jul 2026, 15:35 UTC · 10w ago
Verdict
Headline takes no side. We score LLY +0.90 across four claims — strongly bullish.
+0.90strongly bullish
More positive than 95% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
A leadership change at the FDA has removed a dealmaking freeze, which is expected to lead to a flood of biotech acquisitions.
More positive than 98% of claims this week
Eli Lilly completed four acquisitions in Q1 2026, funded by strong growth in its obesity and diabetes franchise.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 91% of claims this week
Alnylam Pharmaceuticals' stock has fallen 21% YTD despite 187% revenue growth, creating a valuation dislocation that makes it a likely takeover target.
More positive than 76% of claims this week
The iShares Biotechnology ETF (IBB) has returned over 51% over the past year, signaling strong momentum in the sector.
More positive than 64% of claims this week
Which stocks this story touches
More positive than 95% of ticker scores this week
Strong financial growth in obesity and diabetes franchises and an aggressive, successful acquisition strategy.
More positive than 74% of ticker scores this week
Despite stock underperformance, the company shows massive revenue growth and is cited as a highly attractive takeover target.
More positive than 67% of ticker scores this week
Praised as a model for using tuck-in M&A to expand its franchise into new therapeutic areas.
More positive than 62% of ticker scores this week
Positive revenue growth and progress in its obesity program, benefiting from a more favorable FDA deal environment.
More positive than 50% of ticker scores this week
Mentioned as a company traders are watching closely for a potential acquisition.
Near neutral — 90% of ticker scores this week are stronger
Mentioned only as a historical reference for an analyst's accuracy.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Reuters
1d ago
More positive than 36% of relationship scores this week
[mutual] Both companies are competing in the obesity treatment market, with Lilly's Zepbound and Amgen's MariTide program.
−5.2%
Price is moving against the score
$1152.22 vs $1215.83 close before publication (Jul 8) · not market-adjusted
LLY chart →
